Aura Biosciences, Inc.

Rentabilité sur six mois: -19.85%
Rendement en dividendes: 0%
Secteur: Healthcare

6.42 $

0 $ 0%
4.9 $
11.74 $

paper.min_max_per_year

Calendrier des promotions Aura Biosciences, Inc.

À propos de l'entreprise Aura Biosciences, Inc.

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Paramètres de base

IPO date
2021-10-29
ISIN
US05153U1079
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 0 0
P/BV 2.69 6
P/E 0 0
Efficacité
Nom Signification Grade
ROA -39.73 0
ROE -46.01 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.2193 10
Debt/Ratio 0.1028 10
Debt/Equity 0.2009 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 299.93 10
Rentabilité EPS, % 53.56 7

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 6.42 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 6.97 $ 0 $ 0 $ -7.89 % 0 % 0 %
common.calendar.number_days.30d 5.89 $ 6.42 $ 6.42 $ +9 % 0 % 0 %
common.calendar.number_days.90d 5.3 $ 4.9 $ 6.97 $ +21.13 % 0 % 0 %
common.calendar.number_days.180d 8.01 $ 4.9 $ 8.21 $ -19.85 % 0 % 0 %
common.calendar.number_days.1y 7.73 $ 4.9 $ 11.74 $ -16.95 % 0 % 0 %
common.calendar.number_days.3y 13.25 $ 4.9 $ 20.34 $ -51.55 % 0 % 0 %
common.calendar.number_days.5y 4.9 $ 4.9 $ 24.89 $ +131.02 % 0 % 0 %
common.calendar.number_days.10y 4.9 $ 4.9 $ 24.89 $ +131.02 % 0 % 0 %
common.calendar.number_days.ytd 7.85 $ 4.9 $ 8.45 $ -18.22 % 0 % 0 %

Principaux propriétaires

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Elisabet de los Pinos Ph.D. Founder, CEO, President & Director 895.16k 1974 (51 année)
Ms. Julie B. Feder Chief Financial Officer 604.2k 1971 (54 année)
Dr. Mark Plavsic D.V.M., Ph.D. Chief Technology Officer N/A 1961 (64 année)
Mr. Patrick Nealon Senior Vice President of Clinical Development Operations N/A
Dr. Anthony Daniels M.D. Therapeutic Area Head of Ocular Oncology N/A
Dr. Richard Mountfield Ph.D. Senior Vice President of Regulatory Affairs & Quality N/A
Mr. Conor Kilroy General Counsel & Secretary N/A 1982 (43 année)
Dr. Jill J. Hopkins M.D. Chief Medical Officer & President of Research and Development N/A 1965 (60 années)

Informations sur l'entreprise

Adresse: United States, Boston. MA, 80 Guest Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.aurabiosciences.com